文献速递乳腺癌

阿培利司联合氟维司群治疗CDK4/6抑制剂后PIK3CA突变HR阳性晚期乳腺癌:BYLieve研究A队列

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
PubMed 文献 · Lancet Oncol · 2021-01-01

BYLieve是一项正在进行的2期、多中心、开放标签、非比较研究,评估阿培利司联合氟维司群在CDK4/6抑制剂联合芳香化酶抑制剂进展后的PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌患者中的疗效。

要点

  • 常见3级及以上不良事件为高血糖(28%)、皮疹(9%)和斑丘疹(9%)。
  • 该方案在此前接受过CDK4/6抑制剂的患者中显示活性且毒性可控。

核心结论

  • 阿培利司联合氟维司群在CDK4/6抑制剂联合芳香化酶抑制剂进展后的PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌患者中显示活性,毒性可控。

研究设计与样本

  • 正在进行的2期、多中心、开放标签、非比较研究,全球18个国家114个研究地点,A队列纳入127例患者。
  • A队列患者为CDK4/6抑制剂联合芳香化酶抑制剂作为最近一次治疗后进展,接受阿培利司300 mg/日口服联合氟维司群500 mg肌注。
  • 主要终点为经中心确认PIK3CA突变患者中,基于当地评估RECIST v1.1的6个月无疾病进展生存比例。

主要发现

  • 127例患者中,最常见的3级或以上不良事件为高血糖(36例[28%])、皮疹(12例[9%])和斑丘疹(12例[9%])。
  • 33例(26%)患者发生严重不良事件,未报告治疗相关死亡。

临床怎么用

  • 对于CDK4/6抑制剂联合芳香化酶抑制剂进展后的PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌患者,可考虑阿培利司联合氟维司群治疗。
  • 治疗期间需监测高血糖和皮疹等不良反应,多数不良事件可控。

局限性

  • 本研究为非比较性2期研究,无对照组。
  • 主要终点基于当地评估,且样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A. METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide. Participants aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 2 or less, with no more than two previous anticancer treatments and no more than one previous chemotherapy regimen, were enrolled in three cohorts. In cohort A, patients must have had progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as the immediate previous treatment. Patients received oral alpelisib 300 mg/day (continuously) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1. The primary endpoint was the proportion of patients alive without disease progression at 6 months per local assessment using Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with a centrally confirmed PIK3CA mutation. This trial is registered with ClinicalTrials.gov, NCT03056755. FINDINGS: Between Aug 14, 2017, and Dec 17, 2019 (data cutoff), 127 patients with at least 6 months' follow-up were enrolled into cohort A. 121 patients had a centrally confirmed PIK3CA mutation. At data cutoff, median follow-up was 11·7 months (IQR 8·5-15·9). 61 (50·4%; 95% CI 41·2-59·6) of 121 patients were alive without disease progression at 6 months. The most frequent grade 3 or worse adverse events were hyperglycaemia (36 [28%] of 127 patients), rash (12 [9%]), and rash maculopapular (12 [9%]). Serious adverse events occurred in 33 (26%) of 127 patients. No treatment-related deaths were reported. INTERPRETATION: BYLieve showed activity of alpelisib plus fulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 inhibitor plus an aromatase inhibitor. FUNDING: Novartis Pharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021. PMID: 33794206. doi:10.1016/S1470-2045(21)00034-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。